YOLFTbeta
Hainan Huluwa Pharmaceutical Group Co Ltd

Hainan Huluwa Pharmaceutical Group Co Ltd

605199 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

5.30CNY-0.09 (-1.67%)

Price History

Full chart

Market Stats

Previous Close5.39
Open5.33
Day Range5.28 – 5.38
52-Week Range5.15 – 10.37
Volume806.10K
Market Cap2.28B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.01
Dividend Yield0.00%
Beta0.33
50-Day Avg5.86
200-Day Avg6.53

About

Hainan Huluwa Pharmaceutical Group Co., Ltd. research, develops, produces, and sells drugs in the areas of digestive system, respiratory system, anti- infective, anti-virus and other fields in China. It offers pediatrics, gynecology, antibiotics, respiratory, digestive system, cardiovascular and cerebrovascular, nourishment, and other medicine products. The company was founded in 2005 and is based in Haikou, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMs. Jinping Liu
  • Employees2.10K
  • HeadquartersNo. 30, Anyu 1st Road, Haikou, China, 571157, China
  • Websitehttps://www.huluwayaoye.com

Leadership

  • Ms. Jinping LiuGM & Chairman of the Board · b. 1970
  • Ms. Hui YuFinancial Director, Deputy GM & Director · b. 1984
  • Mr. Qingtao WangSecretary · b. 1982
  • Mr. Tianbao WeiDeputy General Manager · b. 1967
  • Wei LiAccounting Supervisor
  • Ms. Jun Ling LiDeputy GM & Director · b. 1968
  • Mr. Pei Hu LiDeputy General Manager · b. 1973

Financials

Income Statement

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue487.35M655.01M983.77M1.31B1.16B1.35B1.52B1.80B1.41B900.84M
Growth (%)-+34.40%+50.19%+32.75%-11.04%+16.53%+11.91%+18.49%-21.26%-36.27%
Cost of Revenue293.21M338.39M381.17M498.09M444.38M546.54M644.31M892.85M744.53M636.47M
Gross Profit194.14M316.62M602.61M807.83M717.33M807.25M870.74M902.33M669.02M264.37M
Gross Margin39.84%48.34%61.25%61.86%61.75%59.63%57.47%50.26%47.33%29.35%
Operating Expense156.76M282.46M486.03M666.28M583.15M740.69M774.12M873.86M936.40M424.13M
Operating Income37.38M34.16M116.58M141.55M134.17M66.56M96.62M28.47M-267.38M-159.76M
Operating Margin7.67%5.22%11.85%10.84%11.55%4.92%6.38%1.59%-18.92%-17.74%
EBITDA82.86M78.49M162.89M197.11M187.00M144.53M162.44M97.95M-163.86M-127.85M
EBITDA Margin17.00%11.98%16.56%15.09%16.10%10.68%10.72%5.46%-11.59%-14.19%
Net Income33.76M22.13M100.54M120.33M121.50M72.14M85.68M10.85M-274.46M-287.37M
Net Income Margin6.93%3.38%10.22%9.21%10.46%5.33%5.66%0.60%-19.42%-31.90%
R&D11.20M19.62M43.33M51.66M51.66M100.43M105.66M113.66M202.08M93.86M
R&D as % of Total Revenue2.30%3.00%4.40%3.96%4.45%7.42%6.97%6.33%14.30%10.42%
Interest Expense11.38M14.49M8.98M14.31M11.26M18.11M18.97M18.55M31.94M40.75M
Interest Expense % of Total Revenue2.33%2.21%0.91%1.10%0.97%1.34%1.25%1.03%2.26%4.52%

Balance Sheet

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets535.95M807.21M1.09B1.09B1.52B1.76B2.31B3.06B2.96B2.60B
Total Liabilities407.26M455.83M487.37M442.67M604.68M830.41M1.30B1.90B2.22B2.14B
Total Equity128.69M351.38M604.61M643.94M916.48M928.21M1.01B1.12B700.55M412.70M
Cash62.18M82.59M181.46M154.09M345.88M487.68M480.37M522.69M254.29M78.21M
Total Debt228.32M146.31M142.10M152.62M283.02M499.21M683.98M1.16B1.00B-
Net Debt166.13M63.72M-39.37M-1.47M-62.86M11.53M203.61M637.43M748.90M901.07M

Cash Flow

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow64.96M89.96M31.80M144.51M3.30M102.48M238.71M28.25M-149.12M136.85M
Investing Cash Flow-63.41M-127.09M-69.43M-55.33M-77.62M-117.10M-411.60M-524.21M-142.48M-
Financing Cash Flow35.78M60.75M133.45M-113.49M261.10M146.32M164.15M553.06M21.83M-
Capital Expenditure40.99M157.58M72.82M58.40M59.42M137.62M392.32M489.20M156.23M83.67M
Free Cash Flow23.98M-67.62M-41.02M86.12M-56.12M-35.14M-153.61M-460.95M-305.35M53.18M
Dividends Paid15.30M13.46M80.56M81.00M8.00M60.02M14.35M31.56M92.16M33.55M
FCF to OCF36.91%-75.16%-129.01%59.59%-1700.52%-34.29%-64.35%-1631.54%204.77%38.86%
Dividend Paid to FCF63.82%-19.91%-196.39%94.06%-14.25%-170.79%-9.34%-6.85%-30.18%63.09%

Earnings

Report DateSep 30, 2020Dec 31, 2020Apr 29, 2021Aug 27, 2021Oct 29, 2021Dec 31, 2021Apr 28, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023
EPS Estimate-----------
EPS Actual0.080.120.060.070.06-0.010.070.070.040.030.10
Surprise-----------
Timing------Pre-market----

Key Statistics & Ratios

Market Cap2.28B
Enterprise Value3.35B
Trailing P/E0.00
Forward P/E0.00
Price / Sales3.60
Price / Book7.83
EPS-1.01
Book Value0.748
Revenue (TTM)634.04M
Gross Profit (TTM)52.62M
EBITDA-269.09M
Profit Margin-63.59%
Operating Margin-87.89%
Return on Equity-73.31%
Return on Assets-8.60%
Shares Outstanding400.11M
Shares Float171.88M
Beta0.33
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20211×
0.15Jun 23, 2021